Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology firm, has announced the acceptance of a poster presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place from December 7-10, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology firm, has announced the acceptance of a poster presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place from December 7-10, 2021. The poster titled "Phase 1b expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ advanced breast cancer" will be presented by Dr. Rachel M. Layman on December 10, 2021, during Poster Session 5 from 7 - 8:30 a.m. CT. The presentation will also be available on Celcuity's website.
Details
News Market Reaction – CELC
The recorded move for CELC in the trading session of this news was +0.28%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that an abstract has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in-person from December 7-10, 2021.
Poster presentation details are provided below.
Title: "Phase 1b expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ advanced breast cancer"
Presenter: Rachel M. Layman, MD
Poster Discussion: Spotlight Poster Discussion 13
Poster Session: Poster Session 5 - Hall 1
Presentation Time: December 10, 2021, 7 - 8:30 a.m. CT (8 - 9:30 a.m. ET)
The poster will be accessible on Celcuity's website at the same time.
For more details about SABCS please visit: https://www.sabcs.org/.
About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123
ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
619-228-5886
SOURCE: Celcuity Inc.
View source version on accesswire.com:
https://www.accesswire.com/675706/Celcuity-to-Present-at-the-2021-San-Antonio-Breast-Cancer-Symposium
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.